Gemcitabine transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 61, Issue 133, 2014, Pages 1339-1343

  Hammond, John S ^a   Franko, Jan ^b   Holloway, Shane E ^c   Heckman, Jason T ^d   Orons, Phillip D ^e   Gamblin, T Clark ^f  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MERCY MEDICAL CENTER   (United States)

^c Baptist Saint Anthony's Hospital   (United States)

^d St Peter's Home Health Care   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Gemcitabine; Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Unresectable

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DEHYDRATION; DISEASE COURSE; DRUG DOSE ESCALATION; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RETROSPECTIVE STUDY; UNRESECTABLE HEPATOCELLULAR CARCINOMA; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906985442     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12720     Document Type: Article

References (30)

1. ACS: Cancer Facts & Figures. American Cancer Society. Atlanta, Georgia, 2007.
2. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT: Hepatocellular Carcinoma. Ann Intern Med 1988;108:390-401.
3. Bartlett D, Carr B, Marsh J: Cancer of the liver. In: DeVita V, Rosenberg S, Heilman S, eds. Cancer: Principles and Practice of Oncology Lippincott Williams & Wilkins, 2004:986-1009.
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
5. Llovet J, Burroughs A, Bruix J: Hepatocellular Carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
6. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
7. Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71. (Pubitemid 34454013)
8. Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, et al.: Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) 2006;18:684-92. (Pubitemid 44464049)
9. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al.: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-903. (Pubitemid 46638989)
10. Vogl T, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, et al.: Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 2006;132:745-55. (Pubitemid 44337935)
11. Taïeb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud J-M, et al.: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003;98:2664-70. (Pubitemid 37509531)
12. Xiong ZP, Zhang YD, Huang F, Liang ZY: Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2007;29:623-5.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
14. NCI-CTEP: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2003.
15. Child C, Turcotte J: The liver and portal hypertension 1964.
16. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
18. Forner A, Reig ME, Rodriguez de Lope C, Bruix J: Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. Semin Liver Dis 2010;30:061-74.
19. Gusani N, Balaa F, Steel J, Geller D, Marsh J, Zajko A, et al.: Treatment of Unresectable Cholangiocarcinoma with Gemcitabine-Based Transcatheter Arterial Chemoembolization (TACE): A Single-Institution Experience. J Gastrointest Surg 2008;12:129-37.
20. Lau WY, Yu SC, Lai EC, Leung TW: Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 2006;202:155-68. (Pubitemid 41831485)
21. Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J: Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. (Pubitemid 36875780)
22. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al.: Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology 2011;140:497-507.e2.
23. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. (Pubitemid 36152543)
24. Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, et al.: Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int 2007;6:259-66. (Pubitemid 46925246)
25. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
26. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al.: Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer. J Clin Oncol 2006;24:3946-52. (Pubitemid 46630743)
27. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al.: Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial. JAMA 2007;297:267-77. (Pubitemid 46143304)
28. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al.: Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. Cardiovasc Intervent Radiol 2009;33:41-52.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-Fdr, et al.: Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008;359:378-90.
30. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.